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Abstract
Summary Persistence with osteoporosis therapy is vital for
fracture prevention. This non-interventional study of post-
menopausal women receiving denosumab in Germany,
Austria, Greece, and Belgium found that persistence with
denosumab remains consistently high after 24 months in pa-
tients at high risk of fracture.
Purpose Continued persistence with osteoporosis therapy is
vital for fracture prevention. This non-interventional study of
clinical practice evaluatedmedication-taking behavior of post-
menopausal women receiving denosumab in Germany,
Austria, Greece, and Belgium and factors influencing
persistence.
Methods Subcutaneous denosumab (60 mg every 6 months)
was assigned according to prescribing information and local
guidelines before and independently of enrollment; outcomes
were recorded during routine practice for up to 24 months.
Persistence was defined as receiving the subsequent injec-
tion within 6 months + 8 weeks of the previous injection
and adherence as administration of subsequent injections
within 6 months ± 4 weeks of the previous injection.
Medication coverage ratio (MCR) was calculated as the
proportion of time a patient was covered by denosumab.
Associations between pre-specified baseline covariates
and 24-month persistence were assessed using multivari-
able logistic regression.
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Results The 24-month analyses included 1479 women (mean
age 66.3–72.5 years) from 140 sites; persistence with
denosumab was 75.1–86.0%, adherence 62.9–70.1%, and
mean MCR 87.4–92.4%. No covariate had a significant effect
on persistence across all four countries. For three countries, a
recent fall decreased persistence; patients were generally older
with chronic medical conditions. In some countries, other co-
variates (e.g., older age, comorbidity, immobility, and pre-
scribing reasons) decreased persistence. Adverse drug reac-
tions were reported in 2.3–6.9% patients.
Conclusions Twenty-four-month persistence with denosumab
is consistently high among postmenopausal women in Europe
and may be influenced by patient characteristics. Further stud-
ies are needed to identify determinants of low persistence.
Keywords Adherence . Compliance . Denosumab .
Non-interventional study . Osteoporosis . Persistence
Introduction
With an aging population, the prevalence of osteoporosis in
Europe is expected to rise by approximately a quarter between
2010 and 2025, resulting in a similar increase in the incidence
of osteoporotic (fragility) fracture [1, 2]. In 2010, there were
3.5 million new fragility fractures among women in the
European Union (EU) [3]. Such fractures are a major cause
of morbidity owing to the pain and immobility with which
they are associated. Moreover, they increase mortality, with
hip fractures being associated with half of the deaths attribut-
able to osteoporosis [2]. Fragility fractures also place a con-
siderable burden on healthcare resources. The majority of hip
fractures result in hospitalization, which is often lengthy, and
costs associated with osteoporosis are expected to reach €46.8
billion by 2025 [2].
Because osteoporosis is a chronic condition requiring long-
term treatment, poor persistence with and adherence to med-
ication are key issues. Adherence (also referred to as compli-
ance) describes the proportion of doses that are taken as pre-
scribed (and also reflects the need for the patient to begin
taking the medication at all), while persistence describes the
duration of time over which the treatment is taken without
exceeding a pre-defined permissible gap between doses [4].
Impairments to these aspects of medicine-taking behavior in
the osteoporosis setting have been associated with increased
fracture risk [5–9]; hence, understanding the factors associated
with suboptimal adherence and persistence has the potential to
improve patient outcomes and reduce the burden placed on
healthcare systems.
Until recently, bisphosphonates have been the mainstay of
treatment for postmenopausal osteoporosis (PMO) and have
demonstrated anti-fracture efficacy [10]. However, oral
bisphosphonates, which are frequently used as a first-line
treatment option, are poorly absorbed if taken with food and
can be associated with gastrointestinal irritation [11, 12].
These issues can lead to low persistence with oral bisphospho-
nate therapy; indeed, 30% of patients or fewer remain on
treatment after 2 years [5, 13–15]. Suboptimal persistence
has also been reported for intravenous bisphosphonates [13].
In patients with osteoporosis, previous osteoporosis thera-
py and a history of fractures have been associated with better
persistence, and a history of falls is associated with improved
compliance [14, 16, 17]; patients with these characteristics are
more likely to be better educated about their disease and the
importance of continuing with treatment. Several studies have
shown that younger age, specifically individuals less than
60 years old versus older age, is associated with lower persis-
tence and adherence [13, 16, 18, 19]. While one study found
no association between age and persistence [14], others have
reported older age to be associated with lower persistence
[17]. The presence of multiple comorbidities has been shown
to be linked to low persistence and adherence. In addition,
patients with poor general health and those who smoke have
been shown to have low persistence [16–18, 20, 21], perhaps
because, in general, such individuals are less likely to take
care of their health.
Denosumab, a fully human monoclonal antibody that se-
lectively targets the RANK ligand, is an alternative
antiresorptive treatment for osteoporosis. In randomized trials,
denosumab 60 mg reduced the risk of fracture compared with
placebo and, compared with bisphosphonates, decreased
markers of bone turnover and was associated with greater
bone mineral density (BMD) increases [22–27]. In patients
with osteoporosis, denosumab is administered subcutaneously
(SC) every 6 months (Q6M) [28]. Several observational stud-
ies of routine clinical practice suggest that a 6- or 12-monthly
dosing regimen may result in improved 12-month persistence
compared with both oral bisphosphonates and quarterly intra-
venous regimens [13–15, 29, 30].
To gain a better understanding of real-world persistence
with SC denosumab Q6M and the factors associated with
persistence, we conducted a non-interventional study of rou-
tine clinical practice in Germany, Austria, Greece, and
Belgium. Results of a pre-specified interim analysis showed
high persistence (87.0–95.3%) and adherence (82.7–89.3%)
and a high medication coverage ratio (MCR; the proportion of
time a patient was covered by denosumab; 91.3–95.4%) at
12 months [31]. A similar study conducted in North
America showed that persistence with denosumab was
81% at 12 months and 50% at 24 months [32, 33]. Few
other studies have examined long-term persistence with
denosumab treatment in clinical practice or have investi-
gated the patient characteristics associated with higher
persistence [13–15, 34]. Here, we report data from the
final 24-month analysis and a multivariable analysis of
factors associated with persistence.
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Methods
Study design
This international, multicenter, prospective, non-
interventional study assessed persistence, adherence, and
MCR in postmenopausal women receiving denosumab in rou-
tine practice in Germany, Austria, Greece, and Belgium.
Enrollment began in 2011, and the study was completed on
31 August 2015. Patients were followed up for 2 years after
their first denosumab injection and were expected to receive
subsequent injections every 6 months.
The methodology has been described previously [31]. In
brief, planned enrollment was approximately 1500 patients
across the four participating countries. To be eligible to par-
ticipate in the study, patients must have been suitable for treat-
ment with, and to have been prescribed, SC denosumab 60mg
Q6M in accordance with the appropriate prescribing informa-
tion (e.g., EU Summary of Product Characteristics or the local
equivalent) for the treatment of PMO and in accordance with
national guidelines. Patients were ineligible for this study if
they were currently enrolled in, or had been enrolled in the
past 6 months in, any other study involving another procedure,
device, or drug, or had any disorder that the investigator felt
may affect their ability to provide informed consent.
To ensure minimal disruption to routine practice, physi-
cians must have decided to prescribe denosumab independent-
ly of, and prior to, enrollment in the study. After the first
denosumab injection, the informed consent and patient enroll-
ment procedures were completed within 4 weeks. At enroll-
ment, all patients completed the eight-item Morisky
Medication Adherence Scale (MMAS-8) questionnaire,
which measures adherent behavior on a scale of 0 to 8 [35].
All other data were collected during routine practice. There
was no requirement for additional tests such as dual-energyX-
ray absorptiometry. Patients were permitted to take concomi-
tant therapies that the investigators deemed necessary. All oc-
currences of adverse drug reactions (ADRs; considered by the
physician to be related to the drug) were to be reported to the
study sponsor (Amgen Inc.) by the physician.
Analyses
The 24-month analyses reported here were prospectively
planned and were to be based on the full analysis set (FAS),
defined as all enrolled women who had provided informed
consent and received at least one injection of denosumab.
Safety outcomes were assessed in the safety analysis set
(SAS), which included all enrolled patients who received at
least one injection of denosumab. At the time of the 24-month
analyses, sign-off on the Investigator Verification page for one
site could not be obtained; all patients from this site were
excluded from the 24-month FAS and SAS analyses. One
patient who had been enrolled in error (and had received one
denosumab injection) was also excluded from the 24-month
FAS (but not the SAS).
Persistence and adherence at 24 months were reported by
country as percentages and 95% confidence intervals (CIs);
MCRs at 24 months were reported by country as means and
95% CIs. Persistence was defined as receipt of the subsequent
injection within 6 months + 8 weeks of the previous injection
and adherence as receiving two consecutive injections within
6 months ± 4 weeks of each other. Sensitivity analyses were
conducted using alternative time windows of 6 months + 4, 6,
and 12 weeks for persistence and 6 months ±6, 8, and
12 weeks for adherence. The rationale for these time periods
has been described previously [31]. Briefly, the definition of
adherence is based on pharmacokinetic/pharmacodynamic da-
ta on the residual effects of denosumab following injection,
while the definition of persistence allows for the practical
delays that patients may face in arranging repeat injections
[31]. The MCR was calculated using the percentage of time
that a patient was covered by denosumab, as assessed from
prescription records, and was based on the assumption that
each injection of denosumab provides 6 months (defined as
183 days) of medication coverage.
Multivariable logistic regression was used to explore asso-
ciations between pre-specified baseline covariates and 24-
month persistence. For each country, a stepwise logistic re-
gression model was used; a p value ≤0.25 was required for a
covariate to enter the model, and a p value ≤0.3 was required
for a covariate to remain in the model. For individual covari-
ates, a p value ≤0.05 was deemed to be statistically significant.
The covariates included are listed in Online Resource 1; clin-
ically relevant covariates were defined retrospectively.
Ethics
All sites obtained local approval in accordance with the ethical
principles of the Declaration of Helsinki. Each site provided
Independent Ethics Committee or Independent Review Board
protocol approval to Amgen along with all documentation
pertaining to each patient before being permitted to participate
in the study. All patients were assured of their right to with-
draw from the study at any time without prejudice.
Results
Study population
A total of 1501 patients were enrolled in the study. Of these,
1500were included in the FAS for the 12-month analysis [31].
Twenty patients from one site were subsequently excluded
from the 24-month analysis because sign-off on the
Investigator Verification Page could not be obtained; one
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patient enrolled in error was also excluded. Hence, a total of
1479 patients from 140 sites were included in the FAS for the
24-month analysis (Fig. 1). The 24-month FAS comprised 579
patients from Germany, 300 from Austria, 299 from Greece,
and 301 from Belgium. In total, 1234 patients completed the
24-month observation period: 461 from Germany, 242 from
Austria, 265 from Greece, and 266 from Belgium. The 24-
month SAS comprised 1480 patients (579 patients from
Germany, 300 from Austria, 300 from Greece, and 301 from
Belgium).
Physician and patient characteristics for the 12-month FAS
have been described previously [31]. These were generally
similar across countries, although patients in Greece were
younger than those in Germany, Austria, and Belgium, and
were less likely to have had a prior fragility fracture [31].
Patient baseline demographics for the 24-month FAS are sum-
marized in Table 1 and were very similar to those in the 12-
month FAS, with the same differences observed between
countries.
Persistence, adherence, and MCR at 24 months
Across the four participating countries, 75.1–86.0% of pa-
tients received a fourth denosumab injectionwithin 6months +
8 weeks of the third injection and were therefore classified as
being persistent with treatment at 24 months (Fig. 2).
Adherence at 24 months (i.e., the proportion of patients who
had received a fourth denosumab injection within
6 months ± 4 weeks of the third injection) was 62.9–70.1%
(Fig. 2) and the mean MCR was 87.4–92.4% (Online
Resource 2). Sensitivity analyses confirmed these results
(Online Resource 3).
Multivariable analysis of factors associated with 24-month
persistence
The results of the analysis for all pre-specified covariates are
presented in Online Resource 1. Covariates deemed to be
clinically relevant are shown in Table 2 and Fig. 3 and are
discussed herein. Given the small number of patients who
were not persistent with treatment at 24 months (299 of
1479 patients), the data described below should be interpreted
with caution.
No covariate achieved the significance level required for
entry into the model for all four countries. The only covariate
to enter the model for three countries (Germany, Greece, and
Belgium) was the occurrence of one or more falls in the
12 months before enrollment. Across these three countries,
persistence rates were lower among patients who had had at
least one fall in the 12 months prior to enrollment compared
with those who had experienced no such falls. This associa-
tion was statistically significant in Germany and Belgium (p-
values of 0.038 and 0.027, respectively) but not in Greece
(p = 0.213). Further analysis of this covariate across all four
countries revealed that patients with a fall in the 12 months
before enrollment were generally older than those without a
fall (49.8 vs 33.5%, respectively, were ≥75 years old, while
19.6 vs 29.7% were <65 years old). In addition, a greater
proportion of those with a fall than without a fall had at least
two chronic medical conditions (44.3 vs 33.1%. respectively).
No other covariates entered the model for Belgium.
Modified Wolfe comorbidity index (MWCI) entered the
model for Germany and Austria. In both countries, persistence
rates were lower in patients whose MWCI was above the
country-specific median (median = 1.0 for both countries)
than in those whose MWCI was equal to or below the
country-specific median. This association was statistically sig-
nificant in Germany, but not in Austria (p = 0.048 and
p = 0.054, respectively). The covariate BReason for prescrib-
ing: multiple risk factors for fracture^ also entered the model
for Germany and Austria. In both countries, persistence rates
were lower in patients for whom this reason was given than in
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Excluded from 24-month 
analysis (N = 21)
• Did not receive denosumab 
 (n = 1)
• Site excluded (n = 20)a
Enrolled  
(N = 1501)
24-month SAS
 (N = 1480)
Discontinued (N = 267)
• Lost to follow-up (n = 86)
• Withdrew consent (n = 77)
• Died (n = 28)
• Other (n = 76)
Enrolled  
(N = 1501)
Completed study
(N = 1234)
• Germany (N = 461)
• Austria (N = 242)
• Greece (N = 265)
• Belgium (N = 266)
Excluded (N = 1)
• Erroneously enrolledb 
24-month FAS 
(N = 1479)
Fig. 1 Study flow diagram. aSite excluded because sign-off on the
Investigator Verification Page could not be obtained. Compared with
the overall population, patients at the excluded site were of similar age;
had fewer comorbidities; were taking fewer concomitant medications at
baseline; had a lower incidence of historical fracture, prior fall, and
discontinuation of prior postmenopausal osteoporosis therapy; had
higher bone mineral density T-scores at total hip; and had less severe
disease. bThis patient received one dose of denosumab and so was
included in the SAS. FAS full analysis set, SAS safety analysis set
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those for whom this reason was not given; however, the asso-
ciation did not reach statistical significance for either country
(p = 0.100 and p = 0.163, respectively).
The covariate BReason for prescribing: failed other available
osteoporosis therapy^ entered the model for Germany and
Greece. In Greece, persistence was higher in patients for
whom this reason was given than in those for whom it was
not given; this association was statistically significant
(p = 0.033). A similar (non-significant) trend was seen in
Germany (p = 0.126).
A number of covariates entered the model only for
Greece. Trends towards lower persistence were seen for
patients aged 75 years or older (vs those <65 years old),
patients with a history of discontinuation of osteoporosis
therapy (vs no history of discontinuation), patients with
the prescribing reason of Bintolerant to other osteoporosis
therapy^ (vs this reason not given), and for current and
former smokers (vs not current or former smoker). The
association was only significant for individuals aged
75 years or older and those with a current smoking status
Table 1 Baseline demographics,
comorbidities, and medical
history (24 months, FAS)
Characteristic Germany
(N = 579)
Austria
(N = 300)
Greece
(N = 299)
Belgium
(N = 301)
Age, years, mean (SD) 72.5 (8.7) 71.0 (9.5) 66.3 (9.2) 71.2 (10.4)
Time since PMO diagnosis,
years, mean (SD)
6.0 (5.7) 6.5 (6.5) 6.4 (6.3) 6.4 (8.2)
Baseline T-score, mean (SD)
Total hip −2.1 (0.8) −2.0 (0.8) −2.03 (0.9) −2.1 (0.9)
Femoral neck −2.3 (0.9) −2.2 (0.8) −2.6 (0.8) −2.5 (0.7)
Lumbar spine −2.7 (1.1) −2.8 (0.9) −2.7 (0.8) −2.2 (1.3)
Smoking status, n (%)
Never 407 (70.3) 212 (70.7) 228 (76.3) 236 (78.4)
Former 52 (9.0) 40 (13.3) 24 (8.0) 32 (10.6)
Current 50 (8.6) 48 (16.0) 47 (15.7) 33 (11.0)
Missing 70 (12.1) 0 (0.0) 0 (0.0) 0 (0.0)
Any chronic medical
conditiona, n (%)
522 (90.2) 250 (83.3) 243 (81.3) 210 (69.8)
Modified Wolfe comorbidity index,
median (Q1, Q3)
1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 3.0)
Prior fragility fracture, n (%) 366 (63.2) 122 (40.7) 92 (30.8) 151 (50.2)
Vertebral 180 (31.1) 28 (9.3) 34 (11.4) 52 (17.3)
Non-vertebral 256 (44.2) 101 (33.7) 65 (21.7) 126 (41.9)
Hip 19 (3.3) 11 (3.7) 13 (4.3) 25 (8.3)
Previous PMO therapy, n (%) 513 (88.6) 252 (84.0) 244 (81.6) 256 (85.0)
Previous PMO therapy in the
12 months before
enrollment, n (%)
447 (77.2) 232 (77.3) 216 (72.2) 222 (73.8)
History of discontinuation of PMO
therapy (other than calcium and
vitamin D), n (%)
Yes 102 (17.6) 59 (19.7) 47 (15.7) 44 (14.6)
No 334 (57.7) 226 (75.3) 215 (71.9) 217 (72.1)
N/A 138 (23.8) 15 (5.0) 37 (12.4) 40 (13.3)
Missing 5 (0.9) 0 (0.0) 0 (0.0) 0 (0.0)
MMAS-8
Total scoreb, mean (SD) 7.0 (1.3) 6.6 (1.5) 6.2 (1.8) 7.1 (1.6)
Low or medium score, n (%) 261 (45.1) 177 (59.0) 186 (62.2) 113 (37.5)
FAS full analysis set,MMAS-8 8-item Morisky Medication Adherence Scale, N/A not applicable, PMO postmen-
opausal osteoporosis, Q quartile, SD standard deviation
a Comprising diabetes, osteoporosis, and hypertension
b Scores calculated fromwomenwho answered all questions in theMMAS-8 questionnaire. Scores ranged from 0
to 8, with high adherence represented by a score of 8, medium adherence by a score of 6–7, and low adherence by
a score of less than 6
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(p = 0.001 and p = 0.025, respectively). In contrast, his-
tory of hip fracture (vs no history of hip fracture), age 65–
74 years (vs <65 years old), the number of concomitant
medications being higher than the country-specific medi-
an (vs the same as the median or lower), and receipt of
previous PMO therapy in the 12 months before enroll-
ment (vs no previous PMO therapy in the 12 months be-
fore enrollment) were associated with higher persistence
but did not reach statistical significance.
Having at least one occurrence of immobility in the
12 months before enrollment entered the model for
Austria and was significantly associated with lower per-
sistence with treatment compared with patients who had
not experienced immobility (p = 0.019). Further analysis
of this covariate across all four countries showed that
individuals with an episode of immobility in the
12 months before enrollment were generally older than
those without an episode of immobility (54.4 vs 34.8%
were ≥75 years old, respectively, and 20.0 vs 28.8% were
<65 years old). Furthermore, 84.8% of patients with an
episode of immobility had at least one chronic medical
condition and 55.2% were taking more than two concom-
itant medications. Having at least two historical fractures
also entered the model for Austria and was associated
with a trend towards higher persistence compared with
patients who had not had two or more historical fractures
(p = 0.053). Having any chronic medical condition en-
tered the model for Germany and was significantly asso-
ciated with higher persistence compared with not having a
chronic condition (p = 0.007).
Safety
Safety was assessed in the 1480 patients included in the SAS.
Across the four countries, 2.3–6.9% of patients reported
ADRs (Table 3). The most frequently reported group of
ADRs were those affecting the musculoskeletal and connec-
tive tissue systems (0.3–2.1% of patients; Table 3); the most
common of these was arthralgia (in 0–0.7% of patients;
Table 3). Across countries, 0.3–1.7% of patients reported
ADRs relating to skin and subcutaneous tissue disorders, in-
cluding pruritus, erythema, and rash (Table 3). Thirty-two
patients (2.2%) discontinued denosumab therapy because of
ADRs, the most frequent of which were skin and subcutane-
ous disorders (n = 8), musculoskeletal and connective tissue
disorders (n = 7), general disorders and administration site
conditions (n = 6), and infections and infestations (n = 6).
Three patients (0.2%) reported serious ADRs, with no fatal
events. The serious ADRs were two cases of osteonecrosis of
the jaw (ONJ) and one case of musculoskeletal pain
(discussed below). No cases of hypocalcemia or anaphylaxis
were reported in any country.
ADRs of osteoporotic fracture (fragility fracture) were re-
ported in 64 women (4.3%), including fractures of the lumbar
spine, humerus, wrist, hip, ribs, and pelvis. One patient (0.1%)
had an atypical femoral fracture. Two independently adjudi-
cated cases of ONJ were reported, both in Germany (Table 3).
Both individuals had risk factors for ONJ (previous bisphos-
phonate use, old age, or invasive dental procedures). One case
resolved after approximately 1 year. The outcome of the other
patient is unknown. A medical history was not available for
the patient with serious musculoskeletal pain. This individual
was hospitalized for bone pain and had concurrent non-serious
pollakiuria.
Discussion
A number of retrospective database studies have reported 2-
year persistence data for denosumab (SC Q6M), with values
ranging from 38 to 62% [13–15]. In German and Swedish
studies, persistence with denosumab was substantially higher
than that seen with intravenous or oral bisphosphonates [13,
14]; in a Hungarian study, persistence was considerably lower
with daily, weekly, and monthly treatments (10–18%) than
with 6-monthly denosumab [15].
Our prospective study reports real-world persistence
data with denosumab over the same period, ranging from
75.1 to 86.0% across the countries studied. This repre-
sents only a small change from the 12-month interim anal-
ysis reported previously, in which persistence with
denosumab at 12 months was 87.0─95.3% [31]. The high
level of persistence observed over 24 months was sup-
ported by a high MCR (87.4–92.4%) and high rates of
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Fig. 2 Persistence with and adherence to denosumab treatment at
24 months. Data are shown as percentages ±95% CIs. Persistence was
defined as receiving the subsequent injection within 6 months + 8 weeks
of the previous injection. Adherence was defined as administration of the
subsequent injection within 6 months ± 4 weeks of the previous injection.
CI confidence interval
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Table 2 Summary of multivariable analysis of persistence with denosumab treatment at 24 months for covariates deemed to be clinically significant
Covariate Germany (N = 579) Austria (N = 300) Greece (N = 299) Belgium (N = 301)
n/N1 (%) n/N1 (%) n/N1 (%) n/N1 (%)
Age
<65 years (reference category) – – 110/133 (82.7) –
65–<75 years 95/103 (92.2)
≥75 years 40/59 (67.8)***
Current smoker
No (reference category) – – 210/248 (84.7) –
Yes 35/47 (74.5)*
Former smoker
No (reference category) – – 226/271 (83.4) –
Yes 19/24 (79.2)
Modified Wolfe comorbidity index
≤Median (reference category) 242/316 (76.6) 128/158 (81.0) – –
>Median 169/237 (71.3)* 98/128 (76.6)
Any chronic medical condition
No (reference category) 16/28 (57.1) – – –
Yes 395/525 (75.2)**
Number of concomitant
medications taken at baseline
≤Median (reference category) – – 134/164 (81.7) –
>Median 111/131 (84.7)
≥1 fall in the 12 months
prior to enrollment
No (reference category) 341/452 (75.4) – 210/247 (85.0) 201/226 (88.9)
Yes 70/101 (69.3)* 35/48 (72.9) 47/60 (78.3)*
≥2 historical fractures
No (reference category) – 180/236 (76.3) – –
Yes 46/50 (92.0)
History of hip fracture
No (reference category) – – 233/282 (82.6) –
Yes 12/13 (92.3)
≥1 occurrence of immobility in
the 12 months prior to enrollment
No (reference category) – 213/264 (80.7) – –
Yes 13/22 (59.1)*
Previous PMO therapy in the
12 months before enrollment
No (reference category) – – 61/81 (75.3) –
Yes 184/214 (86.0)
History of discontinuation of
osteoporosis therapy
No (reference category) – – 184/213 (86.4) –
Yes 38/47 (80.9)
N/A 23/35 (65.7)
Reason for prescribing: failed other
available osteoporosis therapy
No (reference category) 269/375 (71.7) – 128/162 (79.0) –
Yes 142/178 (79.8) 117/133 (88.0)*
Reason for prescribing: multiple
risk factors for fracture
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adherence (62.9–70.1%; lower than persistence owing to
the more stringent definition). Of note, persistence levels
were similar across all four countries studied, regardless
of different cultures, healthcare regulations, and geo-
graphic distribution. In addition, the safety profile of
denosumab was consistent with that in previously pub-
lished reports [23–27, 36, 37].
Differences between our data and those of others may be, in
part, due to the prospective design of our study. The other
studies discussed above were retrospective; hence, the record-
ing of persistence may have been more rigorous in our study.
Furthermore, owing to the prospective design of this study,
patients were aware that their medication-taking behavior was
being observed andmay havemodified their behavior towards
–10
Reduced persistence
–5 0 5
Increased persistence
10
OR (95 % CI)
Reason for prescribing: intolerant to other osteoporosis therapy (ref. category: no) 0.47 (0.19, 1.17)
Previous PMO therapy in the 12 months before enrollment (ref. category: no) 2.31 (0.92, 5.83)
History of hip fracture (ref. category: no) 7.28 (0.77, 69.01)
Number of concomitant medications taken at baseline (ref. category: ≤ median) 1.77 (0.80, 3.91)
Former smoker (ref. category: no) 0.40 (0.11, 1.51)
Modified Wolfe comorbidity index (ref. category: ≤ median) 0.66 (0.44, 1.00)*
0.50 (0.25, 1.01)
≥1 fall in the 12 months prior to enrollment (ref. category: no falls in the 12 months 
prior to enrollment)
0.58 (0.35, 0.97)*
0.55 (0.21, 1.41)
0.41 (0.18, 0.90)*
Reasons for prescribing: failed other available osteoporosis therapy 
(ref. category: no)
1.44 (0.90, 2.30)
2.66 (1.08, 6.54)*
Reason for prescribing: multiple risk factors for fracture (ref. category: no) 0.71 (0.47, 1.07)
0.60 (0.29, 1.23)
Current smoker (ref. category: no) 0.32 (0.12, 0.86)*
Age ≥75 years (ref. category: <65 years) 0.18 (0.06, 0.50)*
Age 65–<75 years (ref. category: <65 years) 2.62 (0.96, 7.16)
History of discontinuation of osteoporosis therapy (ref. category: no) 0.89 (0.31, 2.57)
≥2 historical fractures (ref. category: no) 3.56 (0.99, 12.87)
0.25 (0.08, 0.80)*≥1 occurrence of immobility in the 12 months prior to enrollment (ref. category: no)
Any chronic medical condition (ref. category: no) 3.32 (1.40, 7.89)*
Austria Belgium Germany Greece 
Fig. 3 Multivariable analysis of factors associated with 24-month persistence with denosumab treatment. *p ≤ 0.05. This graph has been cropped;
arrows indicate where error bars exceed the axis limits. CI confidence interval, OR odds ratio, PMO postmenopausal osteoporosis
Table 2 (continued)
Covariate Germany (N = 579) Austria (N = 300) Greece (N = 299) Belgium (N = 301)
n/N1 (%) n/N1 (%) n/N1 (%) n/N1 (%)
No (reference category) 220/291 (75.6) 151/187 (80.7) – –
Yes 191/262 (72.9) 75/99 (75.8) –
Reason for prescribing: intolerant to
other osteoporosis therapy
No (reference category) – – 198/234 (84.6) –
Yes 47/61 (77.0)
Where data are missing, the covariate did not enter the model for the specific country. N1 is the number of patients in the 24-month FAS (n = 1479) with
baseline covariate data for all selected covariates, and n is the number of persistent patients within the covariate group. Percentages are based on N1
FAS full analysis set, N/A not applicable, PMO postmenopausal osteoporosis
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
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being more persistent with treatment [38]. Indeed, another
prospective study of patients in Austria found similarly high
levels of persistence with denosumab at 24 months (83.0%)
[34]. This suggests that interventions monitoring patients’
medication-taking behavior may have a positive impact on
persistence. Strategies to improve persistence proposed on
the basis of our data could be complemented by combining
each dose/injection with simple biochemical tests to measure
response (e.g., by monitoring bone turnover markers), which
may emphasize the importance of treatment to patients.
Indeed, this intervention has been shown to improve persis-
tence in individuals with good responses to treatment [39].
When reporting the multivariate analysis of 24-month per-
sistence, we selected covariates which we deemed clinically
relevant for discussion in this article. A number of covariates
which we did not consider clinically relevant demonstrated
statistically significant associations with 24-month persistence
(e.g., reminder service available, academic center); these are
detailed in Online Resource 1. Of note, other studies have
reported that calcium and vitamin D treatment influences per-
sistence [14, 40]. However, owing to the over-the-counter
accessibility of these medications and the reliance on patient
recall, these data may not be adequately robust and we did not
deem them to be clinically relevant covariates. Given the
small number of patients who were non-persistent in our
study, a high proportion of them would need to have the same
characteristic for statistical significance to be reached; hence,
data from the multivariable analysis should be interpreted with
Table 3 Safety data at 24 months
in the SAS Outcome Germany
(N = 579)
Austria
(N = 300)
Greece
(N = 300)
Belgium
(N = 301)
All adverse drug reactions 40 (6.9) 7 (2.3) 14 (4.7) 9 (3.0)
Leading to discontinuation of denosumab 21 (3.6) 5 (1.7) 3 (1.0) 3 (1.0)
Serious adverse drug reaction 2 (0.3) 0 (0.0) 0 (0.0) 1 (0.3)
Leading to death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Adjudicated positive ONJ 2 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Osteoporotic fracturea 30 (5.2) 4 (1.3) 9 (3.0) 21 (7.0)
Adjudicated positive atypical femoral fracture 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Most frequently reported adverse drug reactions
Musculoskeletal and connective tissue disorders 12 (2.1) 1 (0.3) 2 (0.7) 4 (1.3)
Arthralgia 4 (0.7) 1 (0.3) 0 (0.0) 2 (0.7)
Osteonecrosis of the jaw 2 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Pain in extremity 1 (0.2) 0 (0.0) 1 (0.3) 0 (0.0)
Arthropathy 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Back pain 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0)
Growing pains 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Muscle spasms 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Musculoskeletal pain 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Myalgia 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Osteitis 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Pain in jaw 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Trismus 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Skin and subcutaneous tissue disorders 10 (1.7) 1 (0.3) 4 (1.3) 1 (0.3)
Pruritus 5 (0.9) 0 (0.0) 0 (0.0) 1 (0.3)
Erythema 3 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Pruritus generalized 1 (0.2) 0 (0.0) 2 (0.7) 0 (0.0)
Rash 1 (0.2) 1 (0.3) 1 (0.3) 0 (0.0)
Dry skin 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0)
Skin mass 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0)
Data are shown as n (%). Safety data were analyzed in the SAS (N = 1480)
ONJ osteonecrosis of the jaw, SAS safety analysis set
a Osteoporotic fractures were defined as all fractures excluding those of the skull, facial bones, mandible, meta-
carpus, finger phalanges, toe phalanges, and cervical vertebrae and those not associated with known high trauma
severity (fall from higher than the height of a stool, chair, first rung on a ladder, or equivalent (>20 in. [51 cm]), or
severe trauma other than a fall) and pathological fractures
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caution. Despite this limitation, several covariates were signif-
icantly associated with persistence in at least one country.
Contrary to expectations, patients with falls in the
12 months before enrollment were less likely to be persistent
with treatment than those without falls; this association was
seen in three of the four countries studied (Germany, Greece,
and Belgium). These data contrast with findings from a UK
study of persistence, in which a fall before starting treatment
was associated with improved compliance [16]. It is worth
noting that the latter study classified patients as being persis-
tent if they had received at least one bisphosphonate prescrip-
tion in each 12-month period during follow-up. These data
suggest that physicians in the UK may be more likely than
those in other countries to prioritize osteoporosis treatment
following a fall. In order to try to explain our finding, we
examined the characteristics of patients with and without falls
in the 12 months before enrollment. It was noted that com-
pared with patients who had not had a fall, those with a history
of falls tended to be older, with a greater likelihood of having
at least two chronic medical conditions. Although age and the
presence of a chronic medical condition were not individually
associated with persistence across the same three countries,
we might speculate that the various characteristics of the pa-
tients with a fall history interacted to generate a patient profile
with a tendency for low persistence.
In common with other studies showing that increased co-
morbidity is associated with lower persistence [16, 18, 20],
patients with a high MWCI were less likely to be persistent
with therapy than those with a lower MWCI. Individuals with
multiple comorbidities are likely to have a high medication
burden, which may be confusing and could result in osteopo-
rosis treatment being considered a low priority. In addition,
when attempting to reduce medication burden, physicians and
patients may deprioritize osteoporosis therapy. Patients who
were prescribed denosumab because their previous osteopo-
rosis therapy failed were more likely to be persistent than
those who were not prescribed denosumab for this reason.
Such patients may be better educated regarding their disease
and the need for persistence than patients who have not pre-
viously failed treatment, perhaps as a result of discussions
with physicians at the time of previous treatment failure. In
addition, patients for whom bisphosphonate treatment was
unsuccessful may see denosumab as a last chance. This asso-
ciation was also seen in the Swedish database study of persis-
tence discussed previously [14].
A history of the presence or absence of prior fractures is
known to be associated with higher persistence [17]; however,
this variable only entered the model for Austria. Because the
risk of future fracture increases substantially with the number
of previous fractures, we used a cut-off level of at least two
previous fractures to increase the discrimination between
groups for this covariate. Furthermore, previous fractures
could include fragility fractures; hence, the higher threshold
increases the probability that patients in the fracture group had
experienced fragility fractures. In contrast, also in Austria,
having an episode of immobility in the 12 months before
enrollment was associated with lower persistence than not
having immobility in the same period. This could be because
patients experiencing immobility are likely to be older and
frailer than those who do not have periods of immobility.
The age group covariate was only eligible for entry into the
multivariable model in Greece. Patients aged 75 years or older
had significantly lower persistence with treatment than those
aged less than 65 years, whereas there was a trend towards
higher persistence in individuals aged 65–74 years. Greek
treatment guidelines recommend that, in the absence of other
risk factors, BMD measurements should be carried out when
patients reach 65 years of age; at this point, disease awareness
(and therefore persistence) is likely to be higher than in youn-
ger individuals [41]. Patients older than 75 years may have
more chronic conditions and more concomitant medications
and may therefore deprioritize osteoporosis treatment. In ad-
dition, individuals older than 75 years may be more likely to
forget to book an appointment. Reports in the literature also
vary; while the results of many studies suggest that young age
is associated with lower persistence [16, 18, 19], an investiga-
tion by Lekkerkerker et al. suggested that persistence declines
with age [17]. Therefore, there may be a window of age during
which persistence is optimal.
Our finding that current smokers have lower persistence
than non-smokers is in line with previously published data
[21], suggesting that such individuals may be less likely to
heed health advice than non-smokers.
The facts that no clinically relevant covariates entered the
model for all four countries, that only one entered the model
for three countries, and that the majority of covariates were not
significantly associated with persistence suggest that persis-
tence with denosumab therapy is consistently high across pa-
tient populations. This could partly be responsible for the
higher BMD increases achieved with denosumab than with
other antiresorptives. Furthermore, in most countries, factors
known to be associated with increased fracture risk, such as
age, smoking status, and previous fracture, were not associat-
ed with persistence. This suggests that persistence with
denosumab is generally high, even in patients at high risk of
fracture. The exception was the covariate B≥1 fall in the 12
months prior to enrollment,^ which is associated with an in-
creased risk of fracture [42] but, in our study, was associated
with low persistence. Improving persistence in this patient
group therefore has the potential to have a considerable impact
on fracture rates.
The lower impact of patient characteristics on persistence
with denosumab treatment observed in the current study com-
pared with that in persistence studies of bisphosphonates may
have resulted, in part, from the availability of the long-acting
injectable formulation. Long-acting injectables are generally
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administered by healthcare providers rather than being self-
administered; hence, patients are less likely to be able to de-
viate from the prescribing instructions. Furthermore, longer
dosing intervals between treatments may be preferred by pa-
tients over more frequent dosing regimens [15, 29, 30, 43].
As reported previously, this study had some limitations
[31]. Physicians actively agreed to participate in the study
and came from centers that could support their participation;
therefore, they may not be representative of all physicians and
sites treating women with PMO in Germany, Austria, Greece,
and Belgium or other countries. The study enrolled a high
proportion of patients who had previously received another
osteoporosis medication. This is likely to reflect the higher
proportion of patients in real-world practice who have previ-
ously been treated for osteoporosis compared with those who
are newly diagnosed. It could also be a reflection of country-
specific requirements in which patients are eligible for
denosumab treatment.
MCR as a measure of medication-taking behavior has not
been widely used; however, MCR is similar to the more com-
monly used medication possession ratio (MPR), in that both
describe the proportion of time during which patients have
access to a medication. MPR is well suited to assessment of
oral medications, as it indicates the proportion of days on
which the patient had an adequate supply of medication. It is
less appropriate, however, for long-acting injectable medica-
tions, with which a patient is covered therapeutically for a
certain amount of time [44]. MCR reflects the proportion
of days that a patient is covered with respect to the med-
ication over a given interval after receiving the injection
and is the more appropriate tool for evaluating injectable
medications [31, 45].
Differences in reimbursement criteria across countries may
also have influenced the data; for example, in Austria,
denosumab was only used at second line. However, compar-
ison of patient baseline characteristics showed that the propor-
tion of patients with previous osteoporosis treatment was not
considerably higher in Austria than in the other countries stud-
ied, probably because denosumab had recently been approved
in Europe. The high proportion of patients who had previously
received another osteoporosis medication also suggests that
the women enrolled in this study may have had more severe
disease than the overall osteoporosis population. Furthermore,
although enrollment did not start until approximately 1 year
following the availability of denosumab in Europe, participat-
ing physicians may have been early users of the therapy and
could have therefore selected denosumab as a treatment
for patients with chronic or severe disease. Additionally, pa-
tients may have switched to denosumab treatment following
intolerance or poor adherence to bisphosphonates. Overall,
patient characteristics were similar across countries. It would
therefore be interesting to extend this comparison to countries
in which these variables are likely to be more diverse. Another
consideration is that the study was observational and we were
unable to assess the impact of persistence on fracture risk.
With regard to the multivariable analysis of persistence, and
as noted previously, it was difficult to identify any covariates
that could be used in clinical practice to improve persistence
further. Finally, this study did not assess the number of pa-
tients who refused osteoporosis medication at first prescrip-
tion (primary non-adherence). This was outside the scope of
our study but is nonetheless an important aspect of
medication-taking behavior.
Conclusions
The results of this study show that persistence with
denosumab therapy remains high at 24 months, regardless of
baseline covariates, in patients at high risk of fracture, across
all four European countries studied. The consistently high
level of persistence across the countries indicated that it was
relatively insensitive to differences in culture, healthcare reg-
ulations, and geographic distribution. While acknowledging
the limitations of comparing data from studies of different
designs, persistence in this study appeared higher than that
previously observed with bisphosphonates, with treatments
requiring daily, weekly, or monthly dosing, and, indeed,
higher than in that found in other studies of denosumab.
Furthermore, baseline patient characteristics did not appear
to have a considerable effect on persistence, suggesting that
medication-taking behavior with denosumab is good in a
broad range of patients. Further studies are needed to enable
better characterization of the predictors of low persistence.
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